Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

<p>Tumor response, OS, and PFS. <b>A</b> and <b>B,</b> A summary of (<b>A</b>) best reduction and (<b>B</b>) percent change from baseline in the sum of the diameters of target tumors in each patient with NSCLC treated with nivolumab. <b>C</b> and <b>D,</b> A summary of (<b>C</b>) best reduction and (<b>D</b>) percent change from baseline in the sum of the diameters of target tumors in each patient with gastric cancer (GC) treated with nivolumab. <b>E</b> and <b>F,</b> A summary of the probability of OS in patients with (<b>E</b>) NSCLC and (<b>F</b>) GC. <b>G</b> and <b>H,</b> A summary of the probability of PFS in patients with (<b>G</b>) NSCLC and (<b>H</b>) GC. The 95% CI was determined by the Brookmeyer–Crowley method with log–log transformation. Circles indicate censoring. CR, complete response; SD, stable disease.</p>